



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 984 019 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
08.03.2000 Bulletin 2000/10

(51) Int Cl.7: C07H 17/08, A61K 31/70

(21) Application number: 99306034.2

(22) Date of filing: 29.07.1999

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU

MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 19.08.1998 US 97075 P
19.10.1998 US 104785 P

(71) Applicant: Pfizer Products Inc.
Groton, Connecticut 06340 (US)

(72) Inventors:


- Cheng, Hengmiao
East Lyme, Connecticut 06333 (US)

- Letavic, Michael Anthony
Mystic, Connecticut 06355 (US)
- Ziegler, Carl Bernard
East Lyme, Connecticut 06333 (US)
- Dutra, Jason Kenneth
Salem, Connecticut 06420 (US)
- Bertlnato, Peter
Old Lyme, Connecticut 06371 (US)
- Bronk, Brian Scott
Gales Ferry, Connecticut 06335 (US)

(74) Representative:
Simpson, Alison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
91 Wimpole Street
London W1M 8AH (GB)

(54) C11 carbamates of macrolide antibacterials

(57) This invention relates to compounds of the formula



and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that may be used to treat various bacterial infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial infections

EP 0 984 019 A1

by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.


DescriptionBackground of the Invention

5 [0001] This invention relates to novel C11 carbamate azalide derivatives that are useful as antibacterial and antiprotozoa agents in mammals, including man, as well as in fish and birds. This invention also relates to pharmaceutical compositions containing the novel compounds and to methods of treating bacterial and protozoa infections in mammals, fish and birds by administering the novel compounds to mammals, fish and birds requiring such treatment.

10 [0002] Macrolide antibiotics are known to be useful in the treatment of a broad spectrum of bacterial infections in mammals, fish and birds. Such antibiotics include various derivatives of erythromycin A such as azithromycin which is commercially available and is referred to in United States patents 4,474,768 and 4,517,359, both of which are incorporated herein by reference in their entirety. Additional macrolides are referred to in United States provisional patent application serial number 60/049349, filed June 11, 1997 (Yong-Jin Wu); in United States provisional patent application serial number 60/046150, filed May 9, 1997 (Yong-Jin Wu); in United States provisional patent application serial number 60/063676, filed October 29, 1997 (Yong-Jin Wu); United States provisional patent application serial number 60/063161, filed October 29, 1997 (Yong-Jin Wu); United States provisional patent application serial number 60/054866, filed August 6, 1997 (Wei-Guo Su, Bingwei V. Yang, Robert G. Linde, Katherine E. Brighty, Hiroko Masmune, Yong-Jin Wu, Takushi Kaneko and Paul R. McGuirk); United States provisional patent application serial number 60/049348, filed June 11, 1997 (Brian S. Bronk, Michael A. Letavic, Takushi Kaneko and Bingwei V. Yang); International Application No. PCT/GB97/01810 filed July 4, 1997 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey); International Application No. PCT/GB97/01819, filed July 4, 1997 (Peter Francis Leadlay, James Staunton, and Jesus Cortes); United States); United States provisional patent application serial number 60/070343, entitled "Novel Macrolides", filed January 2, 1998 (John P. Dirlam); and United States provisional patent application entitled "Novel Erythromycin Derivatives", filed January 2, 1998 (Yong-Jin Wu); all of which are incorporated herein by reference in their entirety. Like azithromycin and other macrolide antibiotics, the novel macrolide compounds of the present invention possess potent activity against various bacterial infections as described below.

Summary of the Invention

30 [0003] The present invention relates to compounds of the formula



1

and to pharmaceutically acceptable salts thereof, wherein:

55 X is $-\text{CH}_2\text{NR}^7-$, or $-\text{NR}^7\text{CH}_2-$ wherein the first dash of each of the foregoing X groups is attached to C-10 carbon of the compound of formula 1 and the last dash of each group is attached to the C-8 carbon of the compound of formula 1;

R¹ is hydroxy;

R² is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, cyano, -CH₂S(O)_nR⁸ wherein n is an integer ranging from 0 to 2, -CH₂OR⁸, -CH₂NR⁸R⁹, -(CH₂)_m(C₆-C₁₀ aryl), or -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing R² groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

R³ is an alpha-branched C₂-C₈ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C₆-C₈ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C₂-C₅ alkyl group; a C₃-C₈ cycloalkyl or C₅-C₈ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C₁-C₄ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C₁-C₄ alkyl groups or halo atoms; specific preferred examples of R³ are ethyl, isopropyl, cyclopropyl, sec-butyl, cyclobutyl, cyclopentyl, methylthioethyl, furyl;

15 3Or R³ is phenyl which may be optionally substituted with at least one substituent selected from C₁-C₄ alkyl, C₁-C₄ alkoxy and C₁-C₄ alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano;

R⁴ is H or a hydroxy protecting group;

each R⁵ and R⁶ is independently H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl; or R⁵ and R⁶ may be taken together to form a 4-7 membered saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S, and N, in addition to the nitrogen to which R⁵ and R⁶ are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

20 R⁷ is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

25 each R⁸ and R⁹ is independently H, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, (CH₂)_m(C₆-C₁₀ aryl), (CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C₂-C₁₀ alkyl; and Me is methyl

30 [0004] Preferred compounds of formula 1 include those wherein R¹ is hydroxy, R² is H or methyl, R³ is ethyl, R⁴ is H, R⁵ is H, R⁶ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing R⁶ group are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, R⁷ is H, Me, Et, propyl, butyl, cyclopropylmethyl. Specific preferred compounds having the foregoing general structure include those wherein R⁶ is 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-pyridylethyl, 3-pyridylethyl, 4-pyridylethyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2,3-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,5-dimethoxybenzyl, 2,6-dimethoxybenzyl, 3,4-dimethoxybenzyl, 3,5-dimethoxybenzyl, 3,6-dimethoxybenzyl, 3,4-dimethoxyphenylethyl, allyl, propyl, isopropyl.

35 [0005] The invention also relates to a pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0006] The invention also relates to a method of treating cancer, in particular non-small cell lung cancer, in a mammal, 40 which comprises administering to said mammal a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt or solvate thereof.

[0007] The invention also relates to a method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof.

45 [0008] The term "treatment", as used herein, unless otherwise indicated, includes the treatment or prevention of a bacterial infection or protozoa infection as provided in the method of the present invention.

[0009] As used herein, unless otherwise indicated, the terms "bacterial infection(s)" and "protozoa infection(s)" include bacterial infections and protozoa infections that occur in mammals, fish and birds as well as disorders related to

bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention. Such bacterial infections and protozoa infections, and disorders related to such infections, include the following: pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Staphylococcus aureus*, or *Peptostreptococcus* spp.; pharyngitis, rhinitis, fever, and glomerulonephritis related to infection by *Streptococcus pyogenes*, Groups C and G streptococci, *Clostridium diphtheriae*, or *Actinobacillus haemolyticum*; respiratory tract infections related to infection by *Mycoplasma pneumoniae*, *Legionella pneumophila*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, or *Chlamydia pneumoniae*; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by *Staphylococcus aureus*, coagulase-positive staphylococci (i.e., *S. epidermidis*, *S. hemolyticus*, etc.), *Streptococcus pyogenes*, *Streptococcus agalactiae*, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, *Corynebacterium minutissimum*, *Clostridium* spp., or *Bartonella henselae*; uncomplicated acute urinary tract infections related to infection by *Staphylococcus saprophyticus* or *Enterococcus* spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by *Chlamydia trachomatis*, *Haemophilus ducreyi*, *Treponema pallidum*, *Ureaplasma urealyticum*, or *Neisseria gonorrhoeae*; toxin diseases related to infection by *S. aureus* (food poisoning and Toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by *Helicobacter pylori*; systemic febrile syndromes related to infection by *Borrelia recurrentis*; Lyme disease related to infection by *Borrelia burgdorferi*; conjunctivitis, keratitis, and dacrocystitis related to infection by *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenzae*, or *Listeria* spp.; disseminated *Mycobacterium avium* complex (MAC) disease related to infection by *Mycobacterium avium*, or *Mycobacterium intracellulare*; gastroenteritis related to infection by *Campylobacter jejuni*; intestinal protozoa related to infection by *Cryptosporidium* spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by *Bordetella pertussis*; gas gangrene related to infection by *Clostridium perfringens* or *Bacteroides* spp.; and atherosclerosis related to infection by *Helicobacter pylori* or *Chlamydia pneumoniae*. Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include the following: bovine respiratory disease related to infection by *P. haem.*, *P. multocida*, *H. somnus*, *Mycoplasma bovis*, or *Bordetella* spp.; cow enteric disease related to infection by *E. coli* or protozoa (i.e., coccidia, cryptosporidia, etc.); dairy cow mastitis related to infection by *Staph. aureus*, *Strep. uberis*, *Strep. agalactiae*, *Strep. dysgalactiae*, *Klebsiella* spp., *Corynebacterium*, or *Enterococcus* spp.; swine respiratory disease related to infection by *A. pleuro.*, *P. multocida*, or *Mycoplasma* spp.; swine enteric disease related to infection by *E. coli*, *Lawsonia intracellularis*, *Salmonella*, or *Serpulina hyodysenteriae*; cow footrot related to infection by *Fusobacterium* spp.; cow metritis related to infection by *E. coli*; cow hairy warts related to infection by *Fusobacterium necrophorum* or *Bacteroides nodosus*; cow pink-eye related to infection by *Moraxella bovis*; cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by *E. coli*; skin and soft tissue infections in dogs and cats related to infection by *Staph. epidermidis*, *Staph. intermedius*, *coagulase neg. Staph.* or *P. multocida*; and dental or mouth infections in dogs and cats related to infection by *Alcaligenes* spp., *Bacteroides* spp., *Clostridium* spp., *Enterobacter* spp., *Eubacterium*, *Peptostreptococcus*, *Porphyromonas*, or *Prevotella*. Other bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P. Sanford et al., "The Sanford Guide To Antimicrobial Therapy," 26th Edition, (Antimicrobial Therapy, Inc., 1996).


[0010] The present invention also relates to a method of preparing the above compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein R⁵ is H, R⁶ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, which comprises treating a compound of the formula 2

45

50

55

5



10

15

20

2

25

wherein X, R¹, R², R³ and R⁴ are as defined above, with a compound of the formula HNR⁵R⁶, wherein R⁵ and R⁶ are as defined above.

[0011] In a further aspect of the above process of preparing the compound of formula 1, or a pharmaceutically acceptable salt thereof, the above compound of formula 2 is prepared by treating a compound of the formula 3

30


35

40

45

50

3



55

wherein X, R¹, R², R³ and R⁴ are as defined above, with a suitable reagent such as ethylene carbonate, in the presence of a base such as potassium carbonate, in a liquid such as ethyl acetate at 75 °C.

[0012] The present invention also relates to the above compounds of formula 2, as indicated above, useful in the preparation of the above compounds of formula 1 and pharmaceutically acceptable salts thereof.

[0013] The term "hydroxy protecting group", as used herein, unless otherwise indicated, includes acetyl, benzyloxy-

carbonyl, and various hydroxy protecting groups familiar to those skilled in the art including the groups referred to in T. W. Greene, P. G. M. Wuts, "Protective Groups In Organic Synthesis," (J. Wiley & Sons, 1991).

[0014] The term "halo", as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.

[0015] The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic or branched moieties, or mixtures thereof. It is to be understood that where cyclic moieties are intended, at least three carbons in said alkyl must be present. Such cyclic moieties include cyclopropyl, cyclobutyl and cyclopentyl.

[0016] The term "alkoxy", as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.

[0017] The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.

[0018] The term "5-10 membered heteroaryl", as used herein, unless otherwise indicated, includes aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 5 to 10 atoms in its ring system. Examples of suitable 5-10 membered heteroaryl groups include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, pyrrolyl and thiazolyl.

[0019] The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the present invention. The compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. The compounds of the present invention that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.

[0020] Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and, particularly, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.

[0021] Certain compounds of the present invention may have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them.

[0022] The present invention includes the compounds of the present invention, and the pharmaceutically acceptable salts thereof, wherein one or more hydrogen, carbon or other atoms are replaced by isotopes thereof. Such compounds may be useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays.

Detailed Description of the Invention


[0023] The compounds of the present invention may be prepared according to Scheme 1 below and the description that follows. In the following Schemes, unless otherwise indicated, substituents X, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are as defined above.

45

50

55

Scheme 1



[0024] This invention uses the following macrolide templates as starting materials: desmethyl-azithromycin, desmethyl-isoazithromycin as well as their analogs. Azithromycin can be prepared according to methods described in United States Patent Nos. 4,474,768 and 4,517,359, referred to above. Isoazithromycin can be prepared according to methods

described in European Patent Publication 0508699.

[0025] The foregoing starting materials require proper functional group protection before various modifications can take place, and deprotection after desired modifications are complete. The most commonly used protecting groups for amino moieties in the macrolide compounds of this invention are benzylloxycarbonyl (Cbz) and t-butyloxycarbonyl (Boc) groups. Hydroxyl groups are generally protected as acetates or Cbz carbonates. The relative reactivity of various hydroxyl groups in the macrolide molecules of the general type claimed in this invention has been well established. Such differences in reactivity permit selective modification of different parts of the compounds of this invention.

[0026] In the above Schemes, the C-2' hydroxy group (R⁴ is H) is selectively protected by treating the macrolide compound with one equivalent of acetic anhydride in dichloromethane in the absence of external base to provide the corresponding compound wherein R⁴ is acetyl. The acetyl protecting group may be removed by treating the compound of formula 3 with methanol at 23-65°C for 10-48 hours. The C-2' hydroxy may also be protected with other protecting groups familiar to those skilled in the art, such as the Cbz group. Where X is -CH₂NH-, the C-9 amino group may also require protection before further synthetic modifications are performed. Suitable protecting groups for the amino moiety are Cbz and Boc groups. To protect the C-9 amino group, the macrolide may be treated with t-butyl dicarbonate in anhydrous tetrahydrofuran (THF) or benzylloxycarbonyl N-hydroxysuccinimide ester or benzylchloroformate to protect the amino group as its t-butyl or benzyl carbamate. Both the C-9 amino and C-2' hydroxy may be selectively protected with the Cbz group in one step by treating the compound of formula 2 with benzylchloroformate in THF and water. The Boc group may be removed by acid treatment and the Cbz group may be removed by conventional catalytic hydrogenation. In the following description, it is assumed that, where X is -CH₂NH-, the C-9 amino moiety as well as the C-2' hydroxy group are protected and deprotected as would be deemed appropriate by those skilled in the art.

[0027] In Scheme 1, the compound of formula 3 may be prepared according to methods familiar to those skilled in the art. In step 1 of Scheme 1, the compound of formula 3 is treated with a suitable carbonate forming reagent such as ethylene carbonate, in the presence of a base such as potassium carbonate, in a solvent such as EtOAc, at temperature ranging from 23 to 75°C, to provide the compound of formula 2. In step 2 of Scheme 1, the compound of formula 2 is treated with HNR⁵R⁶ wherein R⁵ and R⁶ are as defined as above, a catalytic amount of pyridine hydrochloride can be added, N-Me-imidazole can be used as both a solvent and catalyst to accelerate the reaction when lipophilic aromatic amines such as fluorobenzyl amine and methoxybenzylamine were used. The resulting solution is stirred at a temperature ranging from 23°C to 75°C for two to five days to provide the compound of formula 1.

[0028] The compounds of the present invention may have asymmetric carbon atoms and therefore exist in different enantiomeric and diastereomeric forms. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers may be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Such separations may also be accomplished through use of standard chiral HPLC. The use of all such isomers, including diastereomer mixtures and pure enantiomers, are considered to be part of the present invention.

[0029] The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to mammals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.

[0030] Those compounds of the present invention that are acidic in nature are capable of forming base salts with various cations. For compounds that are to be administered to mammals, fish or birds such salts must be pharmaceutically acceptable. Where a pharmaceutically acceptable salt is required, it may be desirable to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter to a pharmaceutically acceptable salt in a process analogous to that described above relating to the conversion of pharmaceutically unacceptable acid addition salts to pharmaceutically acceptable salts. Examples of base salts include the alkali metal or alkaline-earth metal salts and particularly the sodium, amine and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium, magnesium, various amine cations, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmaco-

logically acceptable bases with cations such as sodium, potassium, calcium, magnesium, various amine cations, etc., and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.

[0031] The activity of the compounds of the present invention in the treatment of a bacterial, parasitic or protozoal infection, or a disorder related to a bacterial, parasitic or protozoal infection, may be assessed by subjecting the claimed compounds to one or more of the following assays.

10

Assay I

[0032] Assay I, described below, employs conventional methodology and interpretation criteria and is designed to provide direction for chemical modifications that may lead to compounds that circumvent defined mechanisms of macrolide resistance. In Assay I, a panel of bacterial strains is assembled to include a variety of target pathogenic species, including representatives of macrolide resistance mechanisms that have been characterized. Use of this panel enables the chemical structure/activity relationship to be determined with respect to potency, spectrum of activity, and structural elements or modifications that may be necessary to obviate resistance mechanisms. Bacterial pathogens that comprise the screening panel are shown in the table below. In many cases, both the macrolide-susceptible parent strain and the macrolide-resistant strain derived from it are available to provide a more accurate assessment of the compound's ability to circumvent the resistance mechanism. Strains that contain the gene with the designation of ermA/ermB/ermC are resistant to macrolides, lincosamides, and streptogramin B antibiotics due to modifications (methylation) of 23S rRNA molecules by an Erm methylase, thereby generally prevent the binding of all three structural classes. Two types of macrolide efflux have been described; msrA encodes a component of an efflux system in staphylococci that prevents the entry of macrolides and streptogramins while mefA/E encodes a transmembrane protein that appears to efflux only macrolides. Inactivation of macrolide antibiotics can occur and can be mediated by either a phosphorylation of the 2'-hydroxyl (mph) or by cleavage of the macrocyclic lactone (esterase). The strains may be characterized using conventional polymerase chain reaction (PCR) technology and/or by sequencing the resistance determinant. The use of PCR technology in this application is described in J. Sutcliffe et al., "Detection Of Erythromycin-Resistant Determinants By PCR", *Antimicrobial Agents and Chemotherapy*, 40(11), 2562-2566 (1996). The assay is performed in microtiter trays and interpreted according to Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition; Approved Standard, published by The National Committee for Clinical Laboratory Standards (NCCLS) guidelines; the minimum inhibitory concentration (MIC) is used to compare strains. Compounds are initially dissolved in dimethylsulfoxide (DMSO) as stock solutions.

35

Strain Designation	Macrolide Resistance Mechanism(s)
Staphylococcus aureus 1116	susceptible parent
Staphylococcus aureus 1117	ermB
Staphylococcus aureus 0052	susceptible parent
Staphylococcus aureus 1120	ermC
Staphylococcus aureus 1032	msrA, mph, esterase
Staphylococcus hemolyticus 1006	msrA, mph
Streptococcus pyogenes 0203	susceptible parent
Streptococcus pyogenes 1079	ermB
Streptococcus pyogenes 1062	susceptible parent
Streptococcus pyogenes 1061	ermB
Streptococcus pyogenes 1064	ermB
Streptococcus agalactiae 1024	susceptible parent
Streptococcus agalactiae 1023	ermB
Streptococcus pneumoniae 1016	susceptible

(continued)

Strain Designation	Macrolide Resistance Mechanism(s)
Streptococcus pneumoniae 1046	rmB
Streptococcus pneumoniae 1095	rmB
Streptococcus pneumoniae 1175	mefE
Streptococcus pneumoniae 0085	susceptible
Haemophilus influenzae 0131	susceptible
Moraxella catarrhalis 0040	susceptible
Moraxella catarrhalis 1055	erythromycin intermediate resistance
Escherichia coli 0266	susceptible

[0033] Assay II is utilized to test for activity against *Pasteurella multocida* and Assay III is utilized to test for activity against *Pasteurella haemolytica*.

20 Assay II

[0034] This assay is based on the liquid dilution method in microliter format. A single colony of *P. multocida* (strain 59A067) is inoculated into 5 ml of brain heart infusion (BHI) broth. The test compounds are prepared by solubilizing 1 mg of the compound in 125 μ l of dimethylsulfoxide (DMSO). Dilutions of the test compound are prepared using uninoculated BHI broth. The concentrations of the test compound used range from 200 μ g/ml to 0.098 μ g/ml by two-fold serial dilutions. The *P. multocida* inoculated BHI is diluted with uninoculated BHI broth to make a 104 cell suspension per 200 μ l. The BHI cell suspensions are mixed with respective serial dilutions of the test compound, and incubated at 37°C for 18 hours. The minimum inhibitory concentration (MIC) is equal to the concentration of the compound exhibiting 100% inhibition of growth of *P. multocida* as determined by comparison with an uninoculated control.

30 Assay III

[0035] This assay is based on the agar dilution method using a Steers Replicator. Two to five colonies isolated from an agar plate are inoculated into BHI broth and incubated overnight at 37°C with shaking (200 rpm). The next morning, 300 μ l of the fully grown *P. haemolytica* preculture is inoculated into 3 ml of fresh BHI broth and is incubated at 37°C with shaking (200 rpm). The appropriate amounts of the test compounds are dissolved in ethanol and a series of two-fold serial dilutions are prepared. Two ml of the respective serial dilution is mixed with 18 ml of molten BHI agar and solidified. When the inoculated *P. haemolytica* culture reaches 0.5 McFarland standard density, about 5 μ l of the *P. haemolytica* culture is inoculated onto BHI agar plates containing the various concentrations of the test compound using a Steers Replicator and incubated for 18 hours at 37°C. Initial concentrations of the test compound range from 100-200 μ g/ml. The MIC is equal to the concentration of the test compound exhibiting 100% inhibition of growth of *P. haemolytica* as determined by comparison with an uninoculated control.

45 Assay IV

Murine *Staphylococcus aureus* intraperitoneal infection model

[0036] Mice (female CF-1) are allotted to cages (10 per cage) upon their arrival, and allowed to acclimate for a minimum of 48 hours before being used. Mice are infected intraperitoneally with 0.5 ml of a 3 to 5 x 10⁵ colony forming units (CFU)/ml log phase culture of *Staphylococcus aureus* strain UC 6097 in 5% hog gastric mucin. Each experiment has one infected, non-medicated control group. Generally, all mice in a given study can be challenged within 30 to 90 minutes, especially if a repeating syringe (such as a Cornwall® syringe) is used to administer the challenge culture. Thirty minutes after infection has begun, compound treatment is given. It may be necessary for a second person to begin compound dosing if all of the animals have not been challenged at the end of thirty minutes. Subcutaneous doses are administered into the loose skin in the back of the neck whereas oral doses are given by means of a feeding needle. In both cases, a volume of 0.2 ml is used per mouse. A control compound of known efficacy administered by the same route is included in each test. Animals are observed daily, and the number of survivors in each group is recorded for 72 hours (three days) post challenge. The PD₅₀ is a calculated dose at which the compound tested protects 50% of

a group of mice from mortality due to the bacterial infection which would be lethal in the absence of drug treatment.

Assay V

5 Murine Staphylococcus aureus intramammary infection model

[0037] Lactating mice (female CF-1 that gave birth 2 to 5 days prior to the day of infection) (female CF-1) are allotted to cages (1 per cage) upon their arrival, and allowed to acclimate for 24-48 hours before being used. Mice are infected in the L4 mammary gland with 0.1 ml of a 300 to 450 colony forming units (CFU/ml) log phase culture of *Staphylococcus aureus* strain UC 6097. Each experiment has one infected, non-medicated control group. Thirty minutes after infection has begun, compound treatment is given. Subcutaneous doses are administered into the loose skin in the back of the neck whereas oral doses are given by means of a feeding needle. In both cases, a volume of 0.2 ml is used per mouse. The endpoint is the presence or absence of clinical mastitis symptoms and quantitation of bacterial numbers in the mammary glands five days after infection. Bacteria are quantitated by homogenizing the infected gland with 4 volumes of phosphate buffered saline for 30 seconds (Omni International, model TH). The homogenate and dilutions of the homogenate are plated on Brain Heart Infusion Agar, incubated at 37° C overnight, and the colonies counted. The lower limit of detection is 50 CFU/gland. Infected, non-medicated mice have ~ 5 x 10⁹ CFU/gland at the time of necropsy.

20 Assay VI

Determination Of MIC Of *Fusobacterium necrophorum* Isolated Using Anaerobic Plate Dilution Techniques

[0038] Minimum inhibitory concentration (MIC) data may be collected from isolates of *Fusobacterium necrophorum* of cattle and sheep origin. The MIC values for *Fusobacterium necrophorum* are determined using plate dilution techniques and inoculation with a Steer's replicator. The procedures are those outlined in "Methods For Antimicrobial Susceptibility Testing Of Anaerobic Bacteria-Third Edition; Approved Standard" (vol. 13, no. 26, 1993) by the National Committee on Clinical Laboratory Standards (NCCLS). A total of 10 dilutions of the antimicrobials are tested as doubling dilutions of the drug (32 to 0.063 mcg/ml). Control strains of anaerobic bacteria (*Clostridium perfringens* ATCC 13124 and *Bacteroides fragilis* ATCC 25285) are used as controls on each inoculated plate.

[0039] The in vivo activity of the compounds of the present invention can be determined by conventional animal protection studies well known to those skilled in the art, usually carried out in rodents.

[0040] According to one in vivo model, mice are allotted to cages upon their arrival, and allowed to acclimate before being used. Animals are inoculated with a bacterial suspension (*P. multocida* strain 59A006) intraperitoneally. Each experiment has at least 3 non-medicated control groups including one infected with 0.1X challenge dose and two infected with 1X challenge dose; a 10X challenge data group may also be used. Generally, all mice in a given study can be challenged within 30-90 minutes, especially if a repeating syringe (such as a Cornwall® syringe) is used to administer the challenge. Thirty minutes after challenging has begun, the first compound treatment is given.

[0041] The compounds of the present invention, and the pharmaceutically acceptable salts thereof (hereinafter "the active compounds"), may be administered through oral, parenteral, topical, or rectal routes in the treatment of bacterial and protozoal infections. In general, these compounds are most desirably administered in dosages ranging from about 0.2 mg per kg body weight per day (mg/kg/day) to about 200 mg/kg/day in single or divided doses (i.e., from 1 to 4 doses per day), although variations will necessarily occur depending upon the species, weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 4 mg/kg/day to about 50 mg/kg/day is most desirably employed. Variations may nevertheless occur depending upon the species of mammal, fish or bird being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day.

[0042] In the treatment of cancer, in particular non-small cell lung cancer, the active compounds may be administered as described in European patent application publication number 758,549, published February 2, 1997.

[0043] The active compounds may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by the routes previously indicated, and such administration may be carried out in single or multiple doses.

[0044] More particularly, the active compounds may be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous

media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the active compounds are present in such dosage forms at concentration levels ranging from about 5.0% to about 99% by weight.

[0044] For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active compound may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

[0045] For parenteral administration, solutions of an active compound in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

[0046] Additionally, it is also possible to administer the active compounds of the present invention topically and this may be done by way of creams, jellies, gels, pastes, patches, ointments and the like, in accordance with standard pharmaceutical practice.

[0047] For administration to animals other than humans, such as cattle or domestic animals, the active compounds may be administered in the feed of the animals or orally as a drench composition.


[0048] The active compounds may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

[0049] The active compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide phenyl, polyhydroxyethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoylresidues. Furthermore, the active compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

[0050] The following Examples further illustrate the method and intermediates of the present invention. It is to be understood that the present invention is not limited to the specific details of the Examples provided below.

Table 1

The compounds of Examples 1-142 have the general formula 6 as shown below with the R and Y substituents indicated in the table below. The compounds were prepared as described in the general preparations below. In the table, the yield and mass spectra (ms) data apply to the final product.



Compounds	Y	R	MS	Yield
1	Me	4-pyridylmethyl	883.0	57
2	H	4-pyridylmethyl	869.1	43
3	Me	2-pyridylmethyl	883.6	34
4	H	2-pyridylmethyl	869.1	24
5	Me	3-pyridylmethyl	883.1	56
6	H	3-pyridylmethyl	869.1	42
7	Me	4-pyridylethyl	897.1	15.6
8	H	4-pyridylethyl	883.1	40.0
9	Me	2-pyridylethyl	897.1	66.7
10	H	2-pyridylethyl	883.1	49.7
11	Me	3-pyridylethyl	897.1	52.0
12	H	3-pyridylethyl	883.1	40.3
13	Me	1-imidazolepropyl	900.5	28.9
14	H	1-imidazolepropyl	886.5	52.1
15	Me	allyl	832.5	79
16	Me	n-propyl	834.7	90
17	Me	cyclopropyl	832.7	30
18	Me	methoxyethyl	850.6	68
19	Me	methoxypropyl	864.6	82
20	Me	benzyl	882.6	70
21	Me	n-hexyl	876.8	87
22	Me	N,N-ethylmethyl amine	843.6	20
23	H	allyl	818.7	78
24	H	methoxypropyl	850.6	77

Compounds	Y	R	MS	Yield
25	H	n-propyl	820.6	78
26	H	n-butyl	834.8	100
27	H	methoxyethyl	836.8	90
28	H	N,N-ethylmethyl amine	820.6	43
29	Me	morpholino	862.6	
30	H	benzyl	868.9	59
31	H	cyclopropyl	818.6	63
32	H	cyclopentyl	846.6	
33	H	n-hexyl	862.8	
34	Me	n-butyl	848.6	90
35	Me	2-fluorobenzyl	900.3	14.1
36	Me	3-fluorobenzyl	900.3	19.7
37	Me	4-fluorobenzyl	900.3	27.2
38	Me	3,4-difluorobenzyl	918.3	15.8
39	Me	3,5-difluorobenzyl	918.3	17.8
40	Me	2,5-difluorobenzyl	918.3	26.9
41	Me	2-trifluoromethylbenzyl	950.2	35.5
42	Me	3-trifluoromethylbenzyl	950.2	24.4
43	Me	4-trifluoromethylbenzyl	950.2	41.0
44	Me	furylmethyl	872.2	38.3
45	Me	5-methyl furylmethyl	886.5	39.5
46	H	2-fluorobenzyl	886.2	-----
47	H	3-fluorobenzyl	886.2	26.5
48	H	3,4-difluorobenzyl	904.2	21.6
49	H	2,5-difluorobenzyl	904.2	19.2
50	H	3-trifluoromethylbenzyl	936.2	21.4
51	H	4-trifluoromethylbenzyl	936.2	37.3
52	H	furylmethyl	858.2	18.1
53	H	5-methyl furylmethyl	872.2	32.8
54	Me	piperonyl	926.2	46.4
55	H	4-fluorobenzyl	886.5	27.4
56	H	3,5-difluorobenzyl	904.5	28.2
57	H	4-fluorophenethyl	900.5	35.2

C mp unds	Y	R	MS	Yield
58	H	3-fluorophenethyl	900.5	38.7
59	H	2-fluorophenethyl	900.5	25.4
60	Me	2-fluorophenethyl	914.7	27.1
61	Me	3-fluorophenethyl	914.6	20.0
62	Me	4-fluorophenethyl	914.6	22.0
63	Me	ethyl	821.0	78.6
64	H	piperonyl	912.5	50
65)	H	isopropyl	820.5	28
66	Me	4-trifluoromethoxybenzyl	966.7	84
67	Me	3-trifluoromethoxybenzyl	966.7	19.1
68	H	3-trifluoromethoxybenzyl	952.5	73.5
69	H	4-trifluoromethoxybenzyl	952.5	18.1
70	Me	4-pyridylcarbonyl- aminoethyl	940.3	36.7
71	Me	isopropyl	834.7	71.7
72	H	thiophenemethyl	874.7	15.5
73	Me	aminoethyl	835.7	87.5
74	Me	2-methoxybenzyl	912.2	22.3
75	Me	4-methoxybenzyl	912.2	16.4
76	Me	3,4-dimethoxybenzyl	942.21	19
77	Me	4-methylbenzyl	896.2	23.9
78	Me	2,4-dimethylbenzyl	910.2	6.4
79	Me	3-methylbenzyl	896.2	14.7
80	Me	3-aminomethyl benzyl	911.2	36.9
81	Me	4-methoxyphenethyl	926.2	45.6
82	Me	2,5-dimethoxyphenethyl	956.2	8.1
83	Me	2-methoxyphenethyl	926.2	20.9
84	Me	2,3-dimethoxyphenethyl	956.2	19
85	Me	3,4-dimethoxyphenethyl	956.2	14.8
86	Me	2-ethoxyphenethyl	940.3	4.7
87	H	4-ethoxyphenethyl	926.2	43.3
88	H	2,3-dimethoxyphenethyl	942.2	39.2
89	H	3,4-dimethoxybenzyl	928.2	45

	Comp unds	Y	R	MS	Yield
5	90	H	2-ethoxyphenethyl	926.3	28.9
91	Me	4-ethoxyphenethyl	940.3	30.7	
92	H	2,3-dimethoxyphenethyl	942.3	34.8	
93	H	3,5-dimethoxyphenethyl	942.3	32.0	
10	94	H	2,4-dimethylbenzyl	896.0	37.9
95	H	4-phenylbutyl	910.2	39.2	
96	H	3-phenylpropyl	896.2	41.1	
15	97	H	4-methoxybenzyl	898.2	53
98	H	2-methoxybenzyl	898.2	42	
99	H	3-chlorobenzyl	902.6	41	
20	100	H	2,4-dichlorobenzyl	937	33
101	H	3,4-dichlorobenzyl	937	39	
102	H	4-methylbenzyl	882.1	53	
25	103	H	2,5-dimethoxybenzyl	928.1	50
104	H	4-chlorobenzyl	902.6	42	
105	Me	4-phenbutyl	924.2	23.7	
30	106	H	2-methoxyphenethyl	912.2	36.3
107	H	2,3-dimethoxybenzyl	928.2	25.0	
108	H	3-chlorophenethyl	916.6	38.1	
35	109	Me	2,3-dimethoxybenzyl	942.2	22.3
110	Me	3-chlorophenethyl	930.6	20.4	
111	Me	4-chlorophenethyl	930.7	11.3	
40	112	Me	4-methylphenethyl	910.2	26.3
113	Me	3,4-dichlorophenethyl	965.1	6.7	
114	Me	3,5-dimethoxyphenethyl	956.2	27.0	
45	115	Me	2,4-dichlorophenethyl	965.1	9.3
116	Me	3-phenpropyl	910.2	30.2	
117	H	4-chlorophenethyl	916.6	30.6	
50	118	H	3,4-dichlorophenethyl	951.1	4.2
119	Me	N-penylpiperazinyl	951.3	6.1	
120	H	2,2-diphenethyl	972.3	22.5	
55	121	H	ethyl-(2,3-dimethoxyphenyl)-indole	1057	28.7

C	mp unds	Y	R	MS	Yield
5	122	M	ethyl-(2,3-dimehtoxyphenyl)-indole	1071	15.2
10	123	H	3-ethoxy-2-hydroxyphenethyl	942.2	14.7
15	124	H	4-methylphenethyl	896.2	20.3
20	125	Me	4-chlorophenethyl	916.6	12.4
25	126	Me	2,2-diphenylethyl	986.3	15.3
30	127	H	3-methylbenzyl	882.2	28.6
35	128	H	2,4-dichlorophenethyl	951.1	
40	129	Me	3-ethoxy-4-hydroxyphenethyl	956.3	9.3
45	130	H	4-methoxyphenethyl	912.2	36.5
50	131	Me	3-chlorobenzyl	916.6	20.2
55	132	H	3-methoxy-4-hydroxyphenethyl	928.2	18.4
	133	Me	3,4-dichlorobenzyl	951.1	22.8
	134	Me	4-hydroxyphenethyl	912.2	8.8
	135	Me	4-aminophenethyl	911.2	8.7
	136	H	4-hydroxy-phenethyl	898.2	9.8
	137	Me	4-ethylphenethyl	924.2	24.9
	138	Me	4-bromophenethyl	974.0	27.7
	139	H	2,5-dibenzylxyphenethyl	1093	1.3
	140	Me	ethynyl	816.1	
	141	H	4-ethylphenethyl	910.2	11.3
	142	H	4-bromophenethyl	961.1	10.8

45

50


55

General Methods for Preparation of Examples 1-142 in Table 1

[0051]

5

10




15

20

RNH₂
PyHCl (cat), or
N-Me-Imidazole

25

30



35


[0052] **Preparation of 11, 12-carbonate (5):** Azalide derivatives (4) (5 g) were dissolved in EtOAc (75 mL), followed by the addition of ethylene carbonate (5 eq) and K₂CO₃ (1 eq). The resulting solution was stirred at 75 °C for two to five days. Solid K₂CO₃ was first removed by filtration, and the organic layer was extracted with pH 6.0 buffer. To the aqueous layer was added saturated NaHCO₃ solution until pH is greater than 8, and the crude product was extracted with CH₂Cl₂ (2 X 100 mL). The organic layer was dried (Na₂SO₄), and solvent removed *in vacuo* to give the crude product which was purified by flash chromatography using 3% MeOH and 0.5% ammonia in CH₂Cl₂.

[0053] **Preparation of 11-carbamate(6):** 11,12-carbonate of azilide (5) (250 mg-760 mg) was dissolved in the amine (1 ~ 2 mL), catalytic amount of pyridine hydrochloride was added when small aliphatic amines were used, N-Me-imidazole was used as both a solvent and catalyst when lipophilic aromatic amines such as fluorobenzyl amine were used, and neither pyridine hydrochloride nor N-Me-imidazole was added when heterocyclic aromatic amines were used, and the resulting solution was stirred at 23 °C for two to five days. The reaction mixture was then taken up into CH₂Cl₂ (50 ~ 150 mL), and washed with water or 0.5 M pH 7.0 sodium phosphate buffer (5 X 50 ~ 150 mL) to remove the unreacted amine. The organic layer was then washed with brine (50 mL) and dried (Na₂SO₄). The solvent was then removed *in vacuo* to give the crude product which was then purified by flash chromatography using 7:2:1 of hexane/EtOAc/Et₂NH or 3% MeOH and 0.5% ammonia in CH₂Cl₂ to give the product.

55

Table 2

The compounds of Examples 143-151 have the general formula 9 below with the R substituents indicated in the table below. The compounds were prepared as described in general preparations below. In the table, the yield and mass spectra (Ms) data apply to the final product.




Compounds	R	MS	Yield
143	3-Pyridylmethyl amine	897.1	44.6
144	4-Pyridylmethyl amine	897.1	33.5
145	2-Pyridylmethyl amine	897.1	40.4
146	3-Pyridylethyl amine	911.7	52.9
147	4-Pyridylethyl amine	911.7	36.7
248	2-Pyridylethyl amine	911.7	22.9
149	2-Furylmethyl amine	886.5	13.5
150	5-methyl-2-furylmethyl amine	900.2	4.4
151	2-thiophenemethyl amine	902.4	30

General Methods for Preparation of Examples 143-151 in Table 2

[0054]

5

10



15


8

20

 RNH_2
N-Me-Imidazole

25

30



35

9

[0055] Preparation of 4^o-tert-Alcohol carbonate (8): 4^o-tert-Alcohol azalide (7) (1g, 1.31 mmol), ethylene carbonate (700 mg, 7.95 mmol) and K_2CO_3 (215 mg, 1.56 mmol) were mixed in a round bottom flask, followed by the addition of $EtOAc$ (15 mL). The resulting solution was heated to $75\text{ }^\circ C$ for 48 h. Solid K_2CO_3 was filtered off, and the filtrate was diluted with $EtOAc$ (50 mL). The organic layer was washed with water (3 x 50 mL), and dried (Na_2SO_4), and solvent was removed *in vacuo* to give the product, 860 mg (83%).


[0056] Preparation of 4^o-tert-Alcohol Carbamate (9): 4^o-tert-alcohol carbonate (8) (250 mg ~ 760 mg) was dissolved in the amine (1 ~ 2 mL), and the resulting solution was stirred at $23\text{ }^\circ C$ for two to five days. The reaction mixture was then taken up into CH_2Cl_2 (50 ~ 150 mL), and washed with water or 0.5 M pH 7.0 sodium phosphate buffer (5 X 50 ~ 150 mL) to remove the unreacted amine. The organic layer was then washed with brine (50 mL) and dried (Na_2SO_4). The solvent was then removed *in vacuo* to give the crude product which was then purified by flash chromatography using 7:2:1 of hexane/ $EtOAc/Et_2NH$ to give the product.

50

55

Table 3

The compounds of Examples 152-154 have the general formula 12 below with the R substituents indicated in the table below. The compounds were prepared as described in Preparations below. In the table, the yield and mass spectra (ms) data apply to the final product.



12

Compounds	R	MS	Yield
152	3-Pyridylmethyl	1003.8	47.9
153	4-Pyridylmethyl	1003.8	50.4
154	2-methoxyethyl	970.6	45.4

30

35

40


45

50

55

General Methods for Preparation of Examples 152-154 in Table 3

[0057]



35 [0058] **Preparation of 4°-tert-Amino Alcohol carbonate (11):** 4°-tert-Amino alcohol azalide (10) (1g, 1.31 mmol), ethylene carbonate (700 mg, 7.95 mmol) and K₂CO₃ (215 mg, 1.56 mmol) were mixed in a round bottom flask, followed by the addition of EtOAc (15 mL). The resulting solution was heated to 75 °C for 48 h. Solid K₂CO₃ was filtered off, and the filtrate was diluted with EtOAc (50 mL). The organic layer was washed with water (3 x 50 mL), and dried (Na₂SO₄), and solvent was removed *in vacuo* to give the product, 860 mg (83%).

40 [0059] **Preparation of 4°-tert-Amino Alcohol Carbamate (12):** 4°-tert-amino alcohol carbonate (11) (250 mg ~ 760 mg) was dissolved in the amine (1 ~ 2 mL), and the resulting solution was stirred at 23 °C for two to five days. The reaction mixture was then taken up into CH₂Cl₂ (50 ~ 150 mL), and washed with water to remove the unreacted amine. The organic layer was then washed with brine (50 mL) and dried (Na₂SO₄). The solvent was then removed *in vacuo* to give the crude product which was then purified by flash chromatography sing 7:2:1 of hexane/EtOAc/Et₂NH to give the product.

45

Table 4

50 The compounds of Examples 155-215 have the general formula 15 below with the R substituents indicated in the table below. The compounds were prepared as described in


Preparations below. In the table, the yield and mass spectra (ms) data apply to the final product.

5

10

15

20



15

25

30

35

40

45

50

55



Compounds	Y	R	MS	Yield
155	ethyl	2-pyridylmethyl	897.3	38.7
156	ethyl	3-pyridylmethyl	897.2	50.7
157	ethyl	4-pyridylmethyl	897.3	35.2
158	propyl	2-pyridylmethyl	911.2	48.2
159	propyl	3-pyridylmethyl	911.2	43.0
160	propyl	4-pyridylmethyl	911.2	45.8
161	cyclopropylmethyl	2-pyridylethyl	923.2	44.5
162	cyclopropylmethyl	2-pyridylmethyl	937.2	30.9
163	cyclopropylmethyl	3-pyridylmethyl	923.2	29.0
164	cyclopropylmethyl	3-pyridylethyl	937.2	45.7
165	cyclopropylmethyl	4-pyridylmethyl	923.2	46.6
166	cyclopropylmethyl	4-pyridylethyl	937.3	46.0
167	butyl	2-pyridylmethyl	925.6	78.4
168	butyl	3-pyridylmethyl	925.6	71.0
169	butyl	4-pyridylmethyl	925.6	76.3
170	4-pyridylmethyl	1-imidazolepropyl	977.5	49.1
171	4-pyridylmethyl	3-pyridylmethyl	960.5	36.7
172	4-pyridylmethyl	4-pyridylmethyl	960.5	30.6
173	cyclopropylmethyl	1-imidazolepropyl	940.6	70.1
174	butyl	1-imidazolepropyl	942.6	75.3
175	butyl	2-pyridylethyl	939.1	82.2

Compounds	Y	R	MS	Yield
176	butyl	3-pyridylethyl	939.1	88.2
177	butyl	4-pyridylethyl	939.1	82.9
178	pentyl	2-pyridylmethyl	939.1	22.6
179	pentyl	3-pyridylmethyl	939.1	29.3
180	pentyl	4-pyridylmethyl	939.1	25.8
181	hexyl	2-pyridylmethyl	953.2	18.4
182	hexyl	3-pyridylmethyl	953.2	22.0
183	hexyl	4-pyridylmethyl	953.2	28.4
184	3-phenylpropyl	2-pyridylmethyl	987.1	42.9
185	3-phenylpropyl	3-pyridylmethyl	987.1	71.1
186	3-phenylpropyl	4-pyridylmethyl	987.1	35.7
187	heptyl	2-pyridylmethyl	967.2	82.6
188	heptyl	3-pyridylmethyl	967.2	91.1
189	heptyl	4-pyridylmethyl	967.2	53.0
190	octyl	2-pyridylmethyl	981.2	97.5
191	octyl	3-pyridylmethyl	891.2	81.9
192	octyl	4-pyridylmethyl	981.2	47.7
193	nonyl	2-pyridylmethyl	995.6	82.5
194	nonyl	3-pyridylmethyl	995.7	86.8
195	nonyl	4-pyridylmethyl	995.6	52.9
196	3-thiomethyl propyl	2-pyridylmethyl	957.5	89.3
197	3-thiomethyl propyl	3-pyridylmethyl	957.4	87.1
198	3-thiomethyl propyl	4-pyridylmethyl	957.4	88.0
199	4-pentenyl	2-pyridylmethyl	937.4	29.3
200	4-pentenyl	3-pyridylmethyl	937.4	38.2
201	4-pentenyl	4-pyridylmethyl	937.3	30.7
202	3-methyl butyl	2-pyridylmethyl	939.1	44.2
203	3-methyl butyl	3-pyridylmethyl	939.2	60.4
204	3-methyl butyl	4-pyridylmethyl	939.2	55.8
205	2-phenethyl	2-pyridylmethyl	973.1	37.3
206	2-phenethyl	3-pyridylmethyl	973.1	15.1
207	2-phenethyl	4-pyridylmethyl	973.1	13.8
208	phenylpropargyl	2-pyridylmethyl	983.1	27.6

C mponents	Y	R	MS	Yield
209	phenylpropargyl	3-pyridylmethyl	983.1	23.6
210	phenylprópargyl	4-pyridylmethyl	983.1	37.8
211	propyl	2-phenoxyethyl	940.1	30.4
212	butyl	2-phenoxyethyl	954.2	40.8
213	propyl	2-pyridylethyl	925.2	31.3
214	propyl	3-pyridylethyl	925.2	37.5
215	propyl	4-pyridylethyl	925.2	26.7

General Methods for Preparation of Examples 155-215 in Table 4

[0060]

RNH₂ (neat)

50 [0061] Preparation of 9N-Modified Azalide 11,12-Carbonate (14): *N*-desmethyl azithromycin 11,12-carbonate (13) (2 g, 2.63 mmol) and the aldehyde (13.2 mmol) were dissolved in CH₂Cl₂ (25 mL), followed by the addition of AcOH (0.448 mL, 7.89 mmol) and molecular sieves (3 Å, 5 g). After the mixture was stirred at room temperature for 10~15 min, NaB(OAc)₃H (2.80g, 13.2 mmol) was added, and the stirring was continued for 24 h. The reaction was first quenched with NaHCO₃, then diluted with CH₂Cl₂. The organic layer was washed with saturated NaHCO₃ (50 mL), brine (50 mL), and dried (Na₂SO₄). The solvent was then removed in vacuo to give the product, which was pure enough for the next step of the sequence.

55 [0062] Synth sl of 9N-Alkylated 11-Carbamate Azalides (15): 11,12-carbonate of 9N-modified azalide (14) (250 mg ~ 760 mg) was dissolved in the amine (1 ~ 2 mL), and the resulting solution was stirred at 23 °C for two to five


days. The reaction mixture was then taken up into CH_2Cl_2 (50 ~ 150 mL), and washed with water to remove the unreacted amine. The organic layer was then washed with brine (50 mL) and dried (Na_2SO_4). The solvent was then removed *in vacuo* to give the crude product which was then purified by flash chromatography using 7:2:1 of hexane/ $\text{EtOAc/Et}_2\text{NH}$ or 3% MeOH and 0.5% ammonia in CH_2Cl_2 to give the product.

5

Table 5

The compounds of Examples 216-217 have the general formula 18 below with the R substituents indicated in the table below. The compounds were prepared as described in Preparations below. In the table, the yield and mass spectra (ms) data apply to the final product.

15



18

30

Compounds	R	MS	Yield
216	3-Pyridylmethyl	909.4	5.0
217	4-Pyridylmethyl	909.6	9.5

35

40

45

50

55

General Methods for Preparation of Examples 1-2 in Table 5

[0063]

5

10

15

20

25

30


35

40


45

50

55

Ethylene Carbonate
 K_2CO_3 , $EtOAc$, $75\text{ }^\circ C$

▼




[0064] Preparation of N-desmethyl-N-allyl-azithromycin (16): N-desmethyl-azithromycin (13) (10 g, 11.5 mmol) was dissolved in toluene (100 mL), followed by the addition of Et_3N , allyl acetate and $Pd(PPh_3)_4$, the resulting solution was stirred at $80\text{ }^\circ C$ for 7 h and then room temperature overnight. The solvent was then removed *in vacuo* and the product was purified by flash chromatography using 2% MeOH and 0.2% ammonia in CH_2Cl_2 to give 5.1 g product, 49%.

[0065] Preparation of 9N-allyl-11, 12-carbonate of azithromycin (17): Azalide derivatives (16) (3.7 g, 4.8 mmol) was dissolved in $EtOAc$ (75 mL), followed by the addition of ethylene carbonate (23.8 g, 27.0 mmol) and K_2CO_3 (0.7 g, 4.2 mmol). The resulting solution was stirred at $75\text{ }^\circ C$ for three days. Solid K_2CO_3 was first removed by filtration, and the organic layer was extracted with pH 6.0 buffer. To the aqueous layer was added saturated $NaHCO_3$ solution until pH is greater than 8, and the crude product was extracted with CH_2Cl_2 (2 X 100 mL). The organic layer was dried (Na_2SO_4), and solvent removed *in vacuo* to give the product, >99% yield.

[0066] Preparation of 9N-allyl 11-carbamate azalide (18): 11,12-carbonate of N-allyl azalide (17) (250 mg ~ 760 mg) was dissolved in the amine (1 ~ 2 mL), and the resulting solution was stirred at $23\text{ }^\circ C$ for two to five days. The reaction mixture was then taken up into $EtOAc$ (50 ~ 150 mL), and washed with water to remove the unreacted amine. The organic layer was then washed with brine (50 mL) and dried (Na_2SO_4). The solvent was then removed *in vacuo* to give the crude product which was then purified by flash chromatography using 7:2:1 of hexane/ $EtOAc$ / Et_2NH or 3% MeOH and 0.5% ammonia in CH_2Cl_2 to give the product.

Claims

1. A compound of the formula



20 1

or a pharmaceutically acceptable salts thereof, wherein:

25 X is $-\text{CH}_2\text{NR}^7-$, or $-\text{NR}^7\text{CH}_2-$ wherein the first dash of each of the foregoing X groups is attached to C-10 carbon of the compound of formula 1 and the last dash of each group is attached to the C-8 carbon of the compound of formula 1;

30 R¹ is hydroxy;

35 R² is H, C₁-C₁₀ alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀ alkynyl, cyano, $-\text{CH}_2\text{S(O)}\text{R}^8$ wherein n is an integer ranging from 0 to 2, $-\text{CH}_2\text{OR}^8$, $-\text{CH}_2\text{NR}^8\text{R}^9$, $-(\text{CH}_2)_m(\text{C}_6\text{-C}_{10}\text{ aryl})$, or $-(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing R¹ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)}\text{R}^8$, $-\text{OC(O)}\text{R}^8$, $-\text{NR}^8\text{C(O)}\text{R}^9$, $-\text{C(O)}\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{F}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

40 R³ is an C₂-C₈ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C₅-C₈ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C₂-C₅ alkyl group; a C₃-C₈ cycloalkyl or C₅-C₈ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C₁-C₄ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C₁-C₄ alkyl groups or halo atoms;

45 Or R³ is phenyl which may be optionally substituted with at least one substituent selected from C₁-C₄ alkyl, C₁-C₄ alkoxy and C₁-C₄ alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano;

50 R⁴ is H or a hydroxy protecting group;

55 each R⁵ and R⁶ is independently H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, $-(\text{CH}_2)_m\text{C}_6\text{-C}_{10}$ aryl, $-(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)}\text{R}^8$, $-\text{OC(O)}\text{R}^8$, $-\text{NR}^8\text{C(O)}\text{R}^9$, $-\text{C(O)}\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl; or R⁵ and R⁶ may be taken together to form a 4-7 membered saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S, and N, in addition to the nitrogen to which R⁵ and R⁶ are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)}\text{R}^8$, $-\text{OC(O)}\text{R}^8$, $-\text{NR}^8\text{C(O)}\text{R}^9$, $-\text{C(O)}\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

55 R⁷ is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, $-(\text{CH}_2)_m\text{C}_6\text{-C}_{10}$ aryl, $-(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected

from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered het roaryl; each R⁸ and R⁹ is independently H, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, (CH₂)_m(C₆-C₁₀) aryl, (CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C₂-C₁₀ alkyl; and M is methyl

5 2. The compound of claim 1 wherein R¹ is OH.

10 3. The compound of claim 2 wherein R² is hydrogen or methyl R³ is ethyl, R⁴ is H and R⁵ is H.

15 4. The compound of claim 3 wherein R⁶ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, or (CH₂)_m C₆-C₁₀ aryl wherein m is an integer ranging from 0 to 4 and wherein the alkyl, alkenyl, alkynyl, and aryl moieties of the said R⁶ group are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, hydroxy, C₁-C₆ alkyl or C₁-C₆ alkoxy.


20 5. The compound of claim 3 wherein R⁶ is -(CH₂)_m(5-10 membered heteroaryl) wherein m is an integer ranging from 0 to 4 and wherein the heteroaryl moieties of the said R⁶ group are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, hydroxy, C₁-C₆ alkyl or C₁-C₆ alkoxy.

25 6. The compound of Claim 5 wherein R⁶ is 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-pyridylethyl, 3-pyridylethyl, 4-pyridylethyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2,3-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,5-dimethoxybenzyl, 2,6-dimethoxybenzyl, 3,4-dimethoxybenzyl, 3,5-dimethoxybenzyl, 3,6-dimethoxybenzyl, 3,4-dimethoxyphenylethyl, allyl, propyl or isopropyl.

30 7. A pharmaceutical composition for the treatment of a bacterial infection or a protozoa infection in a mammal, fish or bird which comprises a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable carrier.

8. A method of treating a bacterial infection or a protozoa infection in a mammal, fish or bird which comprises administering to said mammal, fish or a bird a therapeutically effective amount of a compound of claim 1.

35 9. A method of preparing a compound of the formula



or a pharmaceutically acceptable salt thereof, wherein:

X is $-\text{CH}_2\text{NR}^7-$, or $-\text{NR}^7\text{CH}_2-$ wherein the first dash of each of the foregoing X groups is attached to C-10 carbon of the compound of formula 1 and the last dash of each group is attached to the C-8 carbon of the compound of formula 1;

R¹ is hydroxy;

5 R² is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, cyano, $-\text{CH}_2\text{S(O)}_n\text{R}^8$ wherein n is an integer ranging from 0 to 2, $-\text{CH}_2\text{OR}^8$, $-\text{CH}_2\text{NR}^8\text{R}^9$, $-(\text{CH}_2)_m(\text{C}_6\text{-C}_{10}\text{ aryl})$, or $-(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing R¹ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)R}^8$, $-\text{OC(O)R}^8$, $-\text{NR}^8\text{C(O)R}^9$, $-\text{C(O)NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

10 R³ is an C₂-C₈ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C₅-C₈ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C₂-C₅ alkyl group; a C₃-C₈ cycloalkyl or C₅-C₈ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C₁-C₄ alkyl groups or halo atoms; or a 3 to 15 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C₁-C₄ alkyl groups or halo atoms;

Or R³ is phenyl which may be optionally substituted with at least one substituent selected from C₁-C₄ alkyl, C₁-C₄ alkoxy and C₁-C₄ alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano;

R⁴ is H or a hydroxy protecting group;

20 each R⁵ and R⁶ is independently H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, $-(\text{CH}_2)_m\text{C}_6\text{-C}_{10}\text{ aryl}$, $-(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)R}^8$, $-\text{OC(O)R}^8$, $-\text{NR}^8\text{C(O)R}^9$, $-\text{C(O)NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl; or

25 R⁵ and R⁶ may be taken together to form a 4-7 membered saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S, and N, in addition to the nitrogen to which R⁵ and R⁶ are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)R}^8$, $-\text{OC(O)R}^8$, $-\text{NR}^8\text{C(O)R}^9$, $-\text{C(O)NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

30 R⁷ is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, $-(\text{CH}_2)_m\text{C}_6\text{-C}_{10}\text{ aryl}$, $-(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, $-\text{C(O)R}^8$, $-\text{OC(O)R}^8$, $-\text{NR}^8\text{C(O)R}^9$, $-\text{C(O)NR}^8\text{R}^9$, $-\text{NR}^8\text{R}^9$, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

35 R⁸ and R⁹ is independently H, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, $(\text{CH}_2)_m(\text{C}_6\text{-C}_{10}\text{ aryl})$, $(\text{CH}_2)_m(5\text{-}10\text{ membered heteroaryl})$, wherein m is an integer ranging from 0 to 4, or C₂-C₁₀ alkyl; and Me is methyl

40 which comprises treating a compound of the formula

45

50


55

5

10

15

20



2

25

wherein X, R¹, R², R³ and R⁴ are defined as above, with a compound of the formula HNR⁵R⁶, wherein R⁵ and R⁶ defined above.


30

35

40

45

50




3

wherein X, R¹, R², R³ and R⁴ are as defined in claim 9 with a C₁-C₄ alkenyl carborate in the presence of a base.

55

11. A compound of the formula



2

25 wherein

R¹ is hydroxy

R² is H, C₁-C₁₀ alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀ alkynyl, cyano, -CH₂S(O)_nR⁸ wherein n is an integer ranging from 0 to 2, -CH₂OR⁸, -CH₂NR⁸R⁹, -(CH₂)_m(C₆-C₁₀ aryl), or -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing R¹ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

R³ is an C₂-C₈ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C₅-C₈ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C₂-C₆ alkyl group; a C₃-C₈ cycloalkyl or C₅-C₈ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C₁-C₄ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C₁-C₄ alkyl groups or halo atoms;

Or R³ is phenyl which may be optionally substituted with at least one substituent selected from C₁-C₄ alkyl, C₁-C₄ alkoxy and C₁-C₄ alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano;

R⁴ is H or a hydroxy protecting group;

each R⁵ and R⁶ is independently H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl; or R⁵ and R⁶ may be taken together to form a 4-7 membered saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S, and N, in addition to the nitrogen to which R⁵ and R⁶ are attached, said saturated ring optionally includes 1 or 2 carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

R⁷ is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hy-

droxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl; each R⁸ and R⁹ is independently H, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkynyl, (CH₂)_m(C₆-C₁₀) aryl, (CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C₂-C₁₀ alkyl; and M is methyl

5 R⁴ is H or a hydroxy protecting group.


12. A compound of the formula

10

15

20

25



30

3

or a pharmaceutically acceptable salt thereof, wherein:

35 R¹ is hydroxy

R² is H, C₁-C₁₀ alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀ alkynyl, cyano, -CH₂S(O)_nR⁸ wherein n is an integer ranging from 0 to 2, -CH₂OR⁸, -CH₂NR⁸R⁹, -(CH₂)_m(C₆-C₁₀ aryl), or -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing R¹ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

40 R³ is an C₂-C₈ alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group any of which may optionally be substituted by one or more hydroxyl groups; a C₅-C₈ cycloalkylalkyl group wherein the alkyl group is an alpha-branched C₂-C₆ alkyl group; a C₃-C₈ cycloalkyl or C₅-C₈ cycloalkenyl group, either of which may optionally be substituted by methyl or one or more hydroxyl or one or more C₁-C₄ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C₁-C₄ alkyl groups or halo atoms;

45 Or R³ is phenyl which may be optionally substituted with at least one substituent selected from C₁-C₄ alkyl, C₁-C₄ alkoxy and C₁-C₄ alkylthio groups, halogen atoms, hydroxyl groups, trifluoromethyl, and cyano;

50 R⁴ is H or a hydroxy protecting group;

each R⁵ and R⁶ is independently H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀ aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl; or R⁵ and R⁶ may be taken together to form a 4-7 membered saturated ring or a 5-10 membered heteroaryl ring, wherein said saturated and heteroaryl rings optionally include 1 or 2 heteroatoms selected from O, S, and N, in addition to the nitrogen to which R⁵ and R⁶ are attached, said saturated ring optionally includes 1 or 2

carbon-carbon double or triple bonds, and said saturated and heteroaryl rings are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

5 R⁷ is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, -(CH₂)_mC₆-C₁₀aryl, -(CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, and wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing R⁵ and R⁶ groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R⁸, -OC(O)R⁸, -NR⁸C(O)R⁹, -C(O)NR⁸R⁹, -NR⁸R⁹, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₆-C₁₀ aryl, and 5-10 membered heteroaryl;

10 each R⁸ and R⁹ is independently H, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, (CH₂)_m(C₆-C₁₀) aryl, (CH₂)_m(5-10 membered heteroaryl), wherein m is an integer ranging from 0 to 4, or C₂-C₁₀ alkyl; and Me is methyl

R⁴ is H or a hydroxy protecting group.

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 6034

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D, X	US 4 517 359 A (KOBREHEL GABRIJELA ET AL) 14 May 1985 (1985-05-14) * examples 1,2,5,7,8,10,11 * ---	11,12	C07H17/08 A61K31/70
D, X	EP 0 508 699 A (MERCK & CO INC) 14 October 1992 (1992-10-14) * examples 1-126 * ---	11,12	
P, D, X	WO 99 35156 A (PFIZER PROD INC ;DIRLAM JOHN PHILIP (US); MCARTHUR HAMISH ALASTAIR) 15 July 1999 (1999-07-15) in particular pages 58,58,89,70 * the whole document * ---	12	
P, D, X	WO 98 56802 A (BRONK BRIAN SCOTT ;LETAVIC MICHAEL ANTHONY (US); YANG BINGWEI VERA) 17 December 1998 (1998-12-17) * the whole document * ---	12	
P, X	WO 98 56801 A (BRONK BRIAN SCOTT ;LETAVIC MICHAEL ANTHONY (US); YANG BINGWEI VERA) 17 December 1998 (1998-12-17) * the whole document * ---	12	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	EP 0 132 944 A (PFIZER) 13 February 1985 (1985-02-13) * the whole document * ---	12	C07H A61K
X	EP 0 109 253 A (PFIZER) 23 May 1984 (1984-05-23) * the whole document * ---	12	
P, X	EP 0 927 722 A (PLIVA PHARM & CHEM WORKS) 7 July 1999 (1999-07-07) * the whole document * ---	12	
		-/-	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
MUNICH	17 December 1999	Bardilli, W	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 6034

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	EP 0 553 353 A (TAISHO PHARMA CO LTD) 4 August 1993 (1993-08-04) * example 11 *	12	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search		Examiner
MUNICH	17 December 1999		Bardilli, W
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 99 30 6034

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EOP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-12-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4517359	A	14-05-1985	YU 59281 A AT 375945 B AT 440081 A BE 892357 A CA 1191843 A CH 655728 A DD 202437 A DE 3140449 A FR 2501212 A GB 2094293 A,B HR 930015 B IT 1200960 B JP 1221784 C JP 57158798 A JP 58058357 B PL 235329 A SE 457084 B SE 8201311 A SI 8110592 A SK 418991 A SU 1287755 A	30-06-1983 25-09-1984 15-02-1984 01-07-1982 13-08-1985 15-05-1986 14-09-1983 13-10-1983 10-09-1982 15-09-1982 30-04-1996 27-01-1989 26-07-1984 30-09-1982 24-12-1983 27-09-1982 28-11-1988 07-09-1982 30-06-1996 11-07-1995 30-01-1987
EP 0508699	A	14-10-1992	US 5985844 A AT 164165 T CA 2064634 A,C DE 69224765 D DE 69224765 T DK 508699 T ES 2113410 T GR 3026677 T HK 1009649 A JP 2503156 B JP 5255375 A LV 12211 A LV 12211 B	16-11-1999 15-04-1998 05-10-1992 23-04-1998 15-10-1998 04-05-1998 01-05-1998 31-07-1998 04-06-1999 05-06-1996 05-10-1993 20-01-1999 20-03-1999
WO 9935156	A	15-07-1999	AU 1444799 A	26-07-1999
WO 9856802	A	17-12-1998	AU 7347598 A HR 980314 A	30-12-1998 30-04-1999
WO 9856801	A	17-12-1998	AU 7228198 A HR 980315 A	30-12-1998 30-04-1999
EP 0132944	A	13-02-1985	US 4464527 A DK 319884 A,B,	07-08-1984 31-12-1984

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 99 30 6034

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-12-1999

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0132944 A		GR 79536 A		30-10-1984
		IE 57564 B		16-12-1992
		JP 60025998 A		08-02-1985
EP 0109253 A	23-05-1984	AT 30237 T		15-10-1987
		AU 544790 B		13-06-1985
		AU 2130983 A		24-05-1984
		CA 1239639 A		26-07-1988
		CA 1250284 A		21-02-1989
		CS 8407926 A		16-07-1985
		CS 8308455 A		16-07-1985
		DD 216017 A		28-11-1984
		DE 3374065 A		19-11-1987
		DK 518683 A,B,		16-05-1984
		EG 16641 A		30-08-1990
		ES 527249 A		01-10-1985
		ES 543638 A		16-01-1986
		FI 834163 A,B,		16-05-1984
		GR 79425 A		22-10-1984
		HU 35273 A		28-06-1985
		IE 56234 B		22-05-1991
		IL 70228 A		31-03-1987
		JP 1040038 B		24-08-1989
		JP 1557268 C		16-05-1990
		JP 59104398 A		16-06-1984
		KR 8500968 B		02-07-1985
		NO 834146 A,B,		16-05-1984
		NZ 206259 A		08-08-1986
		PH 19293 A		04-03-1986
		PH 21560 A		11-12-1987
		PT 77645 A,B		01-12-1983
		SU 1272996 A		23-11-1986
		US 4526889 A		02-07-1985
		YU 197285 A		31-08-1986
		YU 224383 A		30-04-1986
		ZA 8308460 A		26-06-1985
EP 0927722 A	07-07-1999	HR 970714 A		31-10-1999
		CN 1229085 A		22-09-1999
		CZ 9804311 A		14-07-1999
		HU 9803043 A		30-08-1999
		JP 11255793 A		21-09-1999
		NO 986186 A		01-07-1999
		PL 330616 A		05-07-1999
EP 0553353 A	04-08-1993	WO 9206991 A		30-04-1992

EPO FORM P0459
For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 99 30 6034

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-12-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0553353 A	US	5350839 A	27-09-1994

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82